ELL 12Alternative Names: edelfosine-liposomal; liposomal edelfosine; TLC ELL 12
Latest Information Update: 02 May 2007
At a glance
- Originator Elan Corporation
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer